Table 2. Change in Serum Bicarbonate and Frequency of Significant Rise in Serum Bicarbonate by Decongestion Strategy.

Trial/Decongestion Strategy	Baseline Bicarbonate (mEq/L) Mean (SD)	72 or 96 hours Bicarbonate (mEq/L) Mean (SD)	Change in Bicarbonate (mEq/L) Mean (SD)	p-value*
DOSE-AHF
Bolus (N=117)	28.2 (4.2)	29.3 (3.8)	1.1 (3.5)	0.40
Infusion (N=108)	28.0 (4.2)	29.5 (4.0)	1.5 (3.8)
Low Dose (N=110)	28.0 (4.1)	29.0 (3.9)	1.0 (3.6)	0.10
High Dose (N-115)	28.2 (4.2)	29.8 (3.9)	1.6 (3.7)
ROSE-AHF
Dopamine (N=105)	27.4 (4.5)	30.0 (4.6)	2.5 (3.6)	0.37
Nesiritide (N=102)	27.0 (4.0)	29.0 (4.0)	2.1 (3.7)
Placebo (N=102)	27.4 (3.4)	29.7 (3.8)	2.2 (3.3)
CARRESS-HF
Stepped pharmacologic care (N=75)	27.9 (4.4)	31.2 (4.1)	3.3 (3.9)	<0.001
Ultrafiltration (N=69)	28.1 (4.6)	27.2 (4.8)	-0.9 (3.9)

^*p values obtained from linear regression model. Models were adjusting for baseline serum bicarbonate.